Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.
Morning Overview on MSN
GLP-1 drugs fail to slow Alzheimer’s in 2 major trials
Two of the most closely watched Alzheimer clinical trials of the decade have delivered a sobering verdict: GLP-1 drugs that ...
Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...
Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...
ESTERO, FL / ACCESS Newswire / December 4, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), ...
Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of ...
Big claims are made about NMN and its ability to stave off ageing. Does it live up to the hype?
UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing*First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and ...
Electro Optic Systems Holdings Limited ( EOPSF) Discusses Global Expansion and Space Technology Leadership at Drone Conference December 10, 2025 3:00 AM EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback